Acumen Pharmaceuticals discovers and develops targeted therapies for the treatment of Alzheimer's disease. Co.'s primary drug candidate, ACU193, is a humanized monoclonal antibody which selectively targets amyloid-beta oligomers. Co. holds exclusive rights to the program. We show 4 historical shares outstanding datapoints in our ABOS shares outstanding history coverage, used to compute ABOS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABOS market cap history over the course of time is important for investors
interested in comparing ABOS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABOS versus a peer is one thing; comparing
ABOS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABOS can fluctuate over the course of history.
With this page we aim to empower investors researching ABOS by allowing them to research the ABOS market cap history. |
Free ABOS Email Alerts:
Video: The Importance of Market Cap
